Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magic mushroom compound tested for cocaine addiction safety

NCT ID NCT06102434

Symptom relief Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a single 25 mg dose of psilocybin (the active ingredient in magic mushrooms) can be safely given to people with cocaine use disorder who want to quit. Ten adults from Los Angeles will take the drug in a comfortable room with two clinicians present, and their heart rate, blood pressure, and mood will be checked for six hours. Researchers will also follow up remotely for 90 days to monitor any lasting effects. The goal is to see if psilocybin is safe enough to study further as a treatment for cocaine addiction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2029

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a Body Mass Index from 18.5 - 34kg/m\^2 * Score of at least 3 on the Severity of Dependence Scale * Desire to cease cocaine use as indicated by a goal of complete cocaine abstinence on the Thoughts about Abstinence Questionnaire * At least 1, but not more than 10 total lifetime use of a classical psychedelic (5-HT2a agonist) * 0 use of a classical psychedelic in the last year Exclusion Criteria: * History of serious adverse events in response to classical psychedelics including history of Hallucinogen Persisting Perceptive Disorder * Abnormal electrocardiogram based on testing at study entrance * A resting heart rate greater than 90 bpm * Current hypertension (exceeding 140 systolic and 90 diastolic at resting) * Current use of antidepressants or other serotonergic-affecting substances * History of cardiac conditions * History of hepatic or renal impairments * History of stroke or Transient Ischemic Attack * Epilepsy or history of seizures * Immediate family or personal history of psychosis, bipolar disorder, or schizophrenia * Anxiety or mood disorders determined by the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-V) * Must not meet DSM-V criteria for any substance use disorders other than cocaine, caffeine, or nicotine * Must not meet DSM-V criteria for borderline personality or dissociative disorders * Current suicidal ideation or lifetime history of suicide attempts * Arrest for a violent offense * Any clinical condition, history of illness, or laboratory results that may place participants at greater risk as judged by the study physician * Women will not be eligible if trying to get pregnant, pregnant, or lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cocaine use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cocaine dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cocaine use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.